General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 381: Mechanism of action of sildenafil is:

A. 5 alpha reductase inhibitor
B. Antiandrogen
C. Phosphodiesterase-5 inhibitor (Correct Answer)
D. Androgenic

Explanation: **Explanation:** **Mechanism of Action (Correct Answer: C):** Sildenafil is a potent and selective inhibitor of **Phosphodiesterase-5 (PDE-5)**. Under normal physiological conditions, sexual stimulation leads to the release of Nitric Oxide (NO) in the corpus cavernosum. NO activates the enzyme guanylyl cyclase, which increases levels of **cyclic Guanosine Monophosphate (cGMP)**. cGMP causes smooth muscle relaxation and increased blood flow, resulting in an erection. PDE-5 is the enzyme responsible for the degradation of cGMP. By inhibiting PDE-5, sildenafil prevents the breakdown of cGMP, thereby enhancing the vasodilatory effect of NO and maintaining penile erection. **Analysis of Incorrect Options:** * **A. 5-alpha reductase inhibitor:** These drugs (e.g., **Finasteride**, Dutasteride) block the conversion of Testosterone to Dihydrotestosterone (DHT). They are used in Benign Prostatic Hyperplasia (BPH) and male pattern baldness. * **B. Antiandrogen:** These agents (e.g., **Flutamide**, Spironolactone) block androgen receptors or inhibit androgen synthesis. They are used in conditions like prostate cancer or hirsutism. * **D. Androgenic:** These are drugs that mimic male sex hormones (e.g., Methyltestosterone) used for replacement therapy in hypogonadism. **High-Yield Clinical Pearls for NEET-PG:** * **Contraindication:** Sildenafil must **never** be co-administered with **Nitrates** (e.g., Nitroglycerin) as it can cause life-threatening hypotension due to synergistic increases in cGMP. * **Other Uses:** Sildenafil is also FDA-approved for **Pulmonary Arterial Hypertension (PAH)**. * **Side Effects:** Common side effects include headache, flushing, and **blue-tinted vision (Cyanopsia)** due to weak inhibition of PDE-6 in the retina. * **Tadalafil vs. Sildenafil:** Tadalafil has a much longer half-life (~36 hours), often called the "weekend pill."

Question 382: Which of the following routes of administration results in 100 percent bioavailability of a drug?

A. Subcutaneous
B. Intravenous (Correct Answer)
C. Intramuscular
D. Intradermal

Explanation: ### Explanation **Correct Answer: B. Intravenous** **Why Intravenous is Correct:** Bioavailability ($F$) is defined as the fraction of an administered dose of unchanged drug that reaches the systemic circulation. When a drug is administered **Intravenously (IV)**, it is injected directly into the venous system, bypassing all barriers to absorption and the "first-pass metabolism" in the liver. Therefore, the entire dose reaches the systemic circulation immediately, resulting in **100% bioavailability ($F = 1.0$)**. This makes the IV route the gold standard for emergencies where a rapid onset of action is required. **Why Other Options are Incorrect:** * **Subcutaneous (SC) & Intramuscular (IM):** While these routes often have high bioavailability, they are rarely 100%. The drug must first diffuse from the injection site into the local capillaries. Factors such as local blood flow, tissue binding, and molecular size can delay or decrease the total amount of drug reaching the systemic circulation. * **Intradermal:** Similar to SC and IM, this route relies on slow absorption through the dermal vasculature. It is primarily used for sensitivity testing (e.g., Penicillin) or vaccinations (e.g., BCG) rather than systemic delivery. **High-Yield NEET-PG Pearls:** * **Definition:** Bioavailability is calculated by comparing the Area Under the Curve (AUC) of a specific route to the AUC of the IV route: $F = \frac{AUC_{\text{oral}}}{AUC_{\text{IV}}}$. * **First-Pass Metabolism:** This is the primary reason for low bioavailability in **Oral** administration. Major sites include the Liver (most common), Gut wall, and Lungs. * **Pro-drugs:** These are inactive compounds converted to active metabolites. While their *systemic* bioavailability might be high, their *therapeutic* onset depends on metabolic activation. * **Note:** The **Intra-arterial** route also provides 100% bioavailability but is rarely used except for localized action (e.g., anticancer drugs or contrast media).

Question 383: Therapeutic index is a measure of:

A. Safety (Correct Answer)
B. Efficacy
C. Potency
D. Selectivity

Explanation: **Explanation:** **Therapeutic Index (TI)** is a quantitative measurement of the relative **safety** of a drug. It represents the ratio between the dose that produces toxicity and the dose that produces the desired therapeutic effect. Mathematically, it is expressed as: **TI = TD₅₀ / ED₅₀** (or LD₅₀ / ED₅₀ in animal studies), where TD₅₀ is the toxic dose in 50% of the population and ED₅₀ is the effective dose in 50%. A higher TI indicates a wider margin of safety, meaning a large increase in dose is required to reach toxic levels. **Analysis of Incorrect Options:** * **B. Efficacy:** Refers to the maximum response (Emax) a drug can produce, regardless of dose. It is a measure of a drug's effectiveness, not safety. * **C. Potency:** Refers to the amount of drug (dose) required to produce an effect of a given intensity (usually measured by EC₅₀). A more potent drug requires a smaller dose but is not necessarily safer. * **D. Selectivity:** Refers to a drug’s ability to affect a particular receptor or target without affecting others. While related to side effects, it is not the formal definition of the Therapeutic Index. **High-Yield NEET-PG Pearls:** 1. **Narrow Therapeutic Index Drugs:** These require Therapeutic Drug Monitoring (TDM) because their therapeutic and toxic doses are very close. Examples: **W**arfarin, **A**minoglycosides/Anti-epileptics (Phenytoin, Lithium), **D**igoxin, **T**heophylline (**Mnemonic: W.A.D.T**). 2. **Therapeutic Window:** The range of dosages between the minimum effective concentration and the minimum toxic concentration. This is the "clinically safe" range. 3. **Certain Safety Factor:** A more rigorous measure of safety calculated as LD₁ / ED₉₉.

Question 384: Maximum response a drug can produce regardless of its dose is known as:

A. Potency
B. Efficacy (Correct Answer)
C. Intrinsic activity
D. Agonist

Explanation: ### Explanation **1. Why Efficacy is Correct:** **Efficacy** (also known as maximal efficacy or $E_{max}$) refers to the maximum therapeutic effect that a drug can produce, regardless of the dose administered [1]. It is determined by the drug's ability to activate a receptor once bound. On a graded dose-response curve, efficacy is represented by the **height (plateau)** of the curve [1]. If a drug cannot produce a 100% response even at high doses, it has lower efficacy compared to a full agonist [2]. **2. Analysis of Incorrect Options:** * **Potency:** This refers to the **amount (dose)** of a drug required to produce an effect of a given intensity (usually measured as $EC_{50}$) [1]. On a graph, potency is indicated by the position of the curve along the **X-axis (left/right)**. A more potent drug requires a smaller dose but does not necessarily produce a greater maximum effect [1]. * **Intrinsic Activity:** This is a theoretical term (coined by Ariens) describing the capacity of a drug to activate a receptor after binding [2]. It ranges from 0 (antagonist) to 1 (full agonist). While related to efficacy, "efficacy" is the standard term used to describe the actual maximal response observed in a biological system. * **Agonist:** This is a type of drug that binds to a receptor and produces a conformational change that leads to a biological response [3]. It is a category of drug, not the measure of the response itself. **3. High-Yield Clinical Pearls for NEET-PG:** * **Clinical Superiority:** In clinical practice, **efficacy is more important than potency [1].** For example, Furosemide is more efficacious than Chlorothiazide because it can remove more fluid, even if it requires a different dose. * **Graph Interpretation:** * Shift to the **Left** = Increased Potency [3]. * Increase in **Height** = Increased Efficacy [1]. * **Competitive Antagonists:** These decrease potency (shift curve right) but do **not** change efficacy. * **Non-competitive Antagonists:** These decrease efficacy (lower the height of the curve).

Question 385: What does the therapeutic window of a medication refer to?

A. An inventory of treatments recommended for a particular disorder
B. A holistic treatment approach, involving but not limited to a cycle of psychopharmacology
C. A recommended dosage and treatment plan
D. The optimum dosage in which a drug's main effects are obtained with minimal side effects (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. The optimum dosage in which a drug's main effects are obtained with minimal side effects.** The **Therapeutic Window** (or Therapeutic Range) is a pharmacological concept representing the range of drug concentrations in the plasma where the drug is clinically effective without being toxic [2]. * **Lower Limit:** Defined by the **Minimum Effective Concentration (MEC)**—the level below which the drug fails to produce the desired therapeutic effect. * **Upper Limit:** Defined by the **Minimum Toxic Concentration (MTC)**—the level above which adverse effects or toxicity become unacceptable. The goal of clinical dosing is to maintain the steady-state concentration within this "window" to maximize efficacy while minimizing side effects [3]. **Why incorrect options are wrong:** * **Option A:** This describes a **Clinical Protocol** or **Formulary**, not a pharmacological range. * **Option B:** This refers to **Multimodal** or **Integrated Therapy**, which is a clinical management strategy rather than a pharmacokinetic parameter. * **Option C:** This describes a **Dosage Regimen**, which is the practical application of drug administration (e.g., 500mg TDS for 5 days) to achieve the therapeutic window [3]. **NEET-PG High-Yield Pearls:** 1. **Therapeutic Index (TI):** Calculated as $LD_{50} / ED_{50}$ (in animals) or $TD_{50} / ED_{50}$ (in humans) [4]. A higher TI indicates a safer drug. 2. **Narrow Therapeutic Index (NTI) Drugs:** These require **Therapeutic Drug Monitoring (TDM)** because their therapeutic window is small [1]. * *Mnemonic:* **W**arfarin, **T**heophylline, **D**igoxin, **L**ithium, **P**henytoin (**W**hen **T**oxic **D**oses **L**oom **P**recariously). 3. **Steady State:** It takes approximately **4 to 5 half-lives** to reach a stable concentration within the therapeutic window.

Question 386: Fexofenadine is a metabolic product of which of the following drugs?

A. Loratadine
B. Astemizole
C. Cetirizine
D. Terfenadine (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Terfenadine** **Reasoning:** Fexofenadine is the **active acid metabolite** of Terfenadine. Originally, Terfenadine was a popular second-generation H1-antihistamine. However, it was discovered that Terfenadine is a prodrug that undergoes extensive first-pass metabolism in the liver via the **CYP3A4 enzyme** to become Fexofenadine. The medical significance of this conversion is critical for exams: Terfenadine itself is cardiotoxic; it blocks delayed rectifier K+ channels in the heart, leading to **QT interval prolongation** and a life-threatening polymorphic ventricular tachycardia known as **Torsades de Pointes**. This toxicity occurs if CYP3A4 is inhibited (e.g., by erythromycin or ketoconazole). Fexofenadine, however, provides the same antihistaminic benefits without the cardiotoxicity, leading to the withdrawal of Terfenadine from the market. **Analysis of Incorrect Options:** * **A. Loratadine:** It is a prodrug, but its active metabolite is **Desloratadine**. * **B. Astemizole:** Similar to Terfenadine, it was withdrawn due to Torsades de Pointes. Its active metabolite is **Norastemizole**. * **C. Cetirizine:** It is actually the active metabolite of **Hydroxyzine** (a first-generation antihistamine). Cetirizine itself is not a prodrug. **High-Yield Clinical Pearls for NEET-PG:** * **Active Metabolites:** Always remember the pairs: Terfenadine → Fexofenadine; Loratadine → Desloratadine; Hydroxyzine → Cetirizine. * **Safety Profile:** Fexofenadine is considered the least sedating second-generation antihistamine because it does not cross the blood-brain barrier. * **Drug Interactions:** Avoid taking Fexofenadine with fruit juices (like orange or grapefruit) as they inhibit OATP1A2, reducing the drug's absorption.

Question 387: Which of the following statements about the phases of clinical trials for a drug is FALSE?

A. Phase I involves healthy volunteers.
B. Efficacy of the drug can be determined in Phase II.
C. The maximum number of drug failures occurs in Phase III. (Correct Answer)
D. Post-marketing surveillance is conducted in Phase IV.

Explanation: ### Explanation **Why the correct answer is Option C:** The statement "The maximum number of drug failures occurs in Phase III" is **false**. Statistically, the highest rate of drug failure occurs in **Phase II** [1]. This phase acts as the "proof-of-concept" stage where the drug's efficacy is first tested in a small group of patients [1, 2]. Many drugs fail here because they do not show the desired therapeutic effect or exhibit unexpected toxicity [1]. Phase III is the most expensive and time-consuming phase, but because drugs reaching this stage have already shown promise in Phase II, their success rate is relatively higher. **Analysis of Incorrect Options:** * **Option A (True):** Phase I (Human Pharmacology) is primarily conducted on **healthy volunteers** (usually 20–80) to determine safety, tolerability, and pharmacokinetics [3]. *Exception: Cytotoxic drugs (anticancer) are tested directly on patients.* * **Option B (True):** Phase II (Exploratory Trial) is the first time the drug is administered to **patients** (100–300) to establish **efficacy** and determine the optimal dose range [1, 2]. * **Option D (True):** Phase IV (Post-marketing Surveillance) begins after the drug is approved and marketed. It monitors long-term safety and identifies **rare adverse effects** that may not appear in smaller clinical trial populations. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Also known as **Microdosing studies**. It uses sub-therapeutic doses in humans (usually <10) to study pharmacokinetics (PK) early, reducing the risk of failure in Phase I. * **Phase I:** Focuses on **Safety** and Maximum Tolerated Dose (MTD). * **Phase II:** Focuses on **Efficacy** (The "Workhorse" phase). * **Phase III:** Focuses on **Comparison** (Multicentric, randomized controlled trials against a placebo or standard drug). * **Phase IV:** Focuses on **Long-term safety** and rare ADRs (e.g., Phocomelia with Thalidomide).

Question 388: Immune-mediated qualitative drug intolerance is called:

A. Supersensitivity
B. Idiosyncrasy
C. Hypersensitivity (Correct Answer)
D. Hyperacidity

Explanation: **Explanation:** The correct answer is **Hypersensitivity (Option C)**. **1. Why Hypersensitivity is correct:** Hypersensitivity (or drug allergy) is defined as an **immune-mediated** reaction to a drug. It is a **qualitative** abnormality, meaning the reaction is different in nature from the drug's intended pharmacological action (e.g., a skin rash from Penicillin, rather than its antibacterial effect). These reactions occur only in sensitized individuals and are not dose-dependent in the traditional sense. **2. Analysis of Incorrect Options:** * **Supersensitivity (Option A):** This refers to an increased response to a drug due to a denervation or a reduction in the number of endogenous ligands (up-regulation of receptors). It is a physiological change in receptor sensitivity, not an immune response. * **Idiosyncrasy (Option B):** This is a genetically determined abnormal reactivity to a drug. While it is also a **qualitative** abnormality, it is **non-immunological**. A classic example is hemolysis in G6PD-deficient patients after taking Primaquine. * **Hyperacidity (Option D):** This is a clinical condition of excessive gastric acid secretion and is unrelated to drug intolerance mechanisms. **3. NEET-PG High-Yield Pearls:** * **Quantitative vs. Qualitative:** *Hyperreactivity* is a quantitative increase in response (same effect, lower dose), whereas *Hypersensitivity* and *Idiosyncrasy* are qualitative (different effect). * **Coombs & Gell Classification:** Hypersensitivity is divided into four types: Type I (IgE-mediated/Anaphylactic), Type II (Cytotoxic), Type III (Immune-complex), and Type IV (Delayed/Cell-mediated). * **Tachyphylaxis:** Rapidly developing tolerance after repeated doses (e.g., Ephedrine, Tyramine).

Question 389: Intake of which of the following medications is associated with an increased incidence of dry socket?

A. Antihypertensives
B. Antiepileptics
C. Oral hypoglycemics
D. Oral contraceptives (Correct Answer)

Explanation: **Explanation:** **Dry socket (Alveolar Osteitis)** occurs when the blood clot at the site of tooth extraction fails to develop or dislodges prematurely, exposing the underlying bone. **Why Oral Contraceptives (OCPs) are the correct answer:** Oral contraceptives are a well-documented risk factor for dry socket. The high levels of **estrogen** (either exogenous from OCPs or endogenous during the menstrual cycle) increase the activity of the **fibrinolytic system**. Estrogen indirectly stimulates the release of plasminogen activators, which convert plasminogen to plasmin. Plasmin then dissolves the fibrin clot in the extraction socket, leading to its premature loss. Studies suggest that the risk is highest during the first 22 days of the pill cycle. **Analysis of Incorrect Options:** * **A. Antihypertensives:** While some (like Calcium Channel Blockers) cause gingival hyperplasia, they do not directly interfere with the fibrinolytic system or clot stability. * **B. Antiepileptics:** Phenytoin is famously associated with gingival overgrowth, but there is no established link between antiepileptics and an increased incidence of alveolar osteitis. * **C. Oral Hypoglycemics:** While uncontrolled Diabetes Mellitus itself can lead to delayed wound healing and increased infection risk, oral hypoglycemic medications are not independent risk factors for dry socket. **High-Yield Clinical Pearls for NEET-PG:** * **Management:** The mainstay of treatment for dry socket is **symptomatic relief** (irrigation with saline and placement of a medicated dressing like **Zinc Oxide Eugenol**). Antibiotics are generally not required unless systemic infection is present. * **Prevention:** To minimize risk in women taking OCPs, extractions should ideally be performed during the **"placebo period" (Days 23–28)** of the tablet cycle when estrogen levels are lowest. * **Other Risk Factors:** Smoking (most significant), traumatic extraction, and poor oral hygiene.

Question 390: Which of the following drugs inhibits de novo synthesis of purines?

A. Cyclosporine
B. Tacrolimus
C. Mycophenolate (Correct Answer)
D. Infliximab

Explanation: **Explanation:** **Correct Answer: C. Mycophenolate** Mycophenolate mofetil (MMF) is a potent, reversible inhibitor of the enzyme **Inosine Monophosphate Dehydrogenase (IMPDH)**. This enzyme is the rate-limiting step in the **de novo synthesis of guanosine nucleotides (purines)**. While most cells can use the "salvage pathway" to produce purines, T and B lymphocytes are uniquely dependent on the de novo pathway for proliferation. By inhibiting this synthesis, Mycophenolate exerts a selective cytostatic effect on lymphocytes, making it a cornerstone in transplant medicine and autoimmune therapy. **Analysis of Incorrect Options:** * **A & B (Cyclosporine and Tacrolimus):** These are **Calcineurin Inhibitors**. They work by binding to intracellular proteins (Cyclophilin and FKBP-12, respectively) to inhibit calcineurin, thereby preventing the dephosphorylation of NFAT (Nuclear Factor of Activated T-cells). This inhibits the transcription of **Interleukin-2 (IL-2)**, rather than affecting purine synthesis. * **D (Infliximab):** This is a chimeric monoclonal antibody that acts as a **TNF-α (Tumor Necrosis Factor) inhibitor**. It neutralizes the biological activity of TNF-α by binding to its soluble and transmembrane forms, used primarily in Crohn’s disease and Rheumatoid Arthritis. **High-Yield NEET-PG Pearls:** * **Selectivity:** Mycophenolate is preferred over Azathioprine in many regimens because of its higher lymphocyte selectivity and lower incidence of bone marrow suppression. * **Side Effects:** The most common dose-limiting side effects of Mycophenolate are **GI distress** (nausea, diarrhea) and hematological (leukopenia). * **Teratogenicity:** It is associated with "Mycophenolate embryopathy" (ear and facial malformations), making it contraindicated in pregnancy. * **Drug Interaction:** Unlike Azathioprine, Mycophenolate metabolism is **not** affected by Allopurinol.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free